The use of questionnaires for measuring patient-reported side effects of drug: Its importance and methodological challenges

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 3, 2008, Pages 278-296

  Foster, Juliet M ^a,b   van der Molen, Thys ^a,b   Caeser, Manfred ^c   Hannaford, Philip ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Nycomed   (Germany)

Author keywords

Patient outcome assessment; Questionnaires; Side effects; Survey methods

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BETA1A INTERFERON; CARBAMAZEPINE; CICLESONIDE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUTICASONE PROPIONATE; LAMOTRIGINE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; PSYCHOTROPIC AGENT; TEMAZEPAM;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONCURRENT VALIDITY; CONSTRUCT VALIDITY; CONTENT VALIDITY; COUGHING; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; EPILEPSY; EXTRAPYRAMIDAL SYMPTOM; FACE VALIDITY; FATIGUE; HAIR LOSS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; INTERNAL CONSISTENCY; LARYNX DISORDER; LOW DRUG DOSE; METHODOLOGY; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; OVARY CANCER; PATIENT CARE; PERIPHERAL NEUROPATHY; PERSONALITY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; REPRODUCIBILITY; REVIEW; RHINORRHEA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; STANDARDIZATION; TEST RETEST RELIABILITY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

BIAS (EPIDEMIOLOGY); HUMANS; PATIENT-CENTERED CARE; PHARMACEUTICAL PREPARATIONS; PSYCHOMETRICS; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 40949108913     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1533     Document Type: Review

References (69)

1. Center for Drug Evaluation and Research (CDER). Patient-reported outcome measures: use in medical product development to support labeling. 5460 draft. Rockville, MD: US Department of Health and Human Services, 28-3-2006.
2. Aldenkamp AP, van Meel HF, Baker GA, Brooks I, Hendriks MP. The A-B neuropsychological assessment schedule (ABNAS): the relationship between patient-perceived drug related cognitive impairment and results of neuropsychological tests. Seizure 2002; 11: 231-237.
3. Lindstrom E, Lewander T, Malm U, Malt UF, Lublin H, Ahlfors UG. UKU-SERS-Pat - the UKU side effect self-rating scale. Eur Psychiatry 2002; 17: 193S.
4. Aldenkamp AP, Arends J, Bootsma HPR, et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002; 43: 19-126.
5. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001; 15: 163-169.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004; 329: 15-19.
7. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-1956.
8. FitzGerald M, Chan CK, Boulet LP. Medication use, asthma control and oropharyngeal side effects in a population of canadian asthma patients. Proc Am Thorac Soc 2006; 3: A593.
9. Mohr D, Likosky W, Boudewyn A, et al. Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-1a. Mult Scler 1998; 4: 487-489.
10. Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288-1293.
11. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997; 68: 377-392.
12. Canonica GW, Dahl R, Kaliner MA, Valovirta EJ, Baena-Cagnani CE, Blaiss MS. Global asthma physician & patient (GAPP) survey: satisfaction with current asthma medications in Europe - adult findings. Proc Am Thorac Soc 2006; 3: 1982.
13. Larsen EB, Genlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93: 381-388.
14. Kjellgren KI, Ahlner J, Dahlof B, Gill H, Hedner T, Saljo R. Patients' and physicians' assessment of risks associated with hypertension and benefits from treatment. J Cardiovasc Risk 1998; 5: 161-166.
15. Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? Qual Saf Health Care 2001; 10: 39i-43.
16. De Geest S. Moons P. The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients. Nephrol Dial Transplant 2000; 15: 457-459.
17. Edwards JE, Oldman A, Smith L, Mcquay HJ, Moore RA. Women's knowledge of, and attitudes to, contraceptive effectiveness and adverse health effects. Br J Fam Plan 2000; 26: 73-80.
18. Jarernsiripornkul N, Krska J, Capps PA, Richards RM, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53: 318-325.
19. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc SciMed 2005; 61: 133-155.
20. Boulet LP, FitzGerald M, Chan CK. Physicians perception and management of oro-pharyngeal symptoms in asthmatic patients using inhaled corticosteroids. Proc Am Thorac Soc 2006; 3: A593.
21. Kroenke K. Studying symptoms: sampling and measurement issues. Ann Intern Med 2001; 134: 844-853.
22. Juniper E, Guyatt G, Streiner D, King D. Clinical impact versus factor analysis for quality of life questionnaire construction. J Clin Epidemiol 1997; 50: 233-238.
23. Ghiselli EE, Campbell JP, Zedeck S. Measurement Theory for the Behavioral Sciences. W.H. Freeman and Company: San Francisco, 1981.
24. Streiner D, Norman G. Health Measurement scales. A Practical Guide to Their Development and Use. Oxford University Press: Oxford, 1995.
25. Lerner EB, Jehle DV, Janicke DM, Moscati RM. Medical communication: do our patients understand? Am J Emerg Med 2000; 18: 764-766.
26. Cosentino M, Leoni O, Onia C, et al. Hospital-based survey of doctors' attitudes to adverse drug reactions and perception of drug-related risk for adverse reaction occurrence. Pharmacoepidemiol Drug Saf 1999; 8: S27-S35.
27. Kubota K, Kubota N, Pearce GL, Inman WH. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring. Eur J Clin Pharmacol 1996; 49: 431-437.
28. Moscovici S. Foreword. In Health and illness: A Social Psychological Analysis, Herzlich C (ed.). Academic Press: London, 1973.
29. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; (1): CD003987.
30. Day JC, Wood G, Dewey M, Bentall RP. A self-rating scale for measuring neuroleptic side-effects - validation in a group of schizophrenic-patients. Br J Psychiatry 1995; 166: 650-653.
31. Aldenkamp AP, Baker G, Pieters MSM, Schoemaker HC, Cohen AF, Schwabe S. The neurotoxicity scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995; 20: 229-239.
32. Bent S, Padula A, Avins AL. Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 2006; 144: 257-261.
33. Bachman JG, Omalley PM. Yea-saying, nay-saying, and going to extremes - black-white differences in response styles. Pub Opin Quar 1984; 48: 491-509.
34. Watson D. Intraindividual and interindividual analyses of positive and negative affect - their relation to health complaints, perceived stress, and daily activities. J Pers Soc Psychol 1988; 54: 1020-1030.
35. Kolk AM, Hanewald GJ, Schagen S. Gijsbers van Wijk CM. A symptom perception approach to common physical symptoms. Soc Sci Med 2003; 57: 2343-2354.
36. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect - the panas scales. J Pers Soc Psychol 1988; 54: 1063-1070.
37. Jordan S, Knight J, Pointon D. Monitoring adverse drug reactions: scales, profiles, and checklists. Int Nurs Rev 2004; 51: 208-221.
38. Moons P, De Geest S, Versteven K, et al. Psychometric properties of the "Modified Transplant Symptom Occurrence and Symptom Distress Scale". J Nurs Meas 2001; 9: 115-134.
39. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The Uku side-effect rating-scale - a new comprehensive rating-scale for psychotropic-drugs and a cross-sectional study of side-effects in neuroleptic-treated patients - preface. Acta Psychiatr Scand 1987; 76: 7-&.
40. Brown V, Sitzia J, Richardson A, Hughes J, Hannon H, Oakley C. The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy. Int J Nurs Stud 2001; 38: 497-510.
41. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-955.
42. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112: 469-478.
43. Clinical Standards Board for Scotland. Clinical standards for schizophrenia. 2001; Edinburgh, CSBS.
44. Aldenkamp AP, Baker GA. The Neurotoxicity Scale-II: results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Epilepsy Res 1997; 27: 165-173.
45. Brooks J, Baker GA, Aldenkamp AP. The A-B neuropsychological assessment schedule (ABNAS): the further refinement of a patient-based scale of patient-perceived cognitive functioning. Epilepsy Res 2001; 43: 227-237.
46. Dott SG, Weiden P, Hopwood P, et al. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists. CNS Spectr 2001; 6: 333-338.
47. Hopwood P. Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy. Breast 1998; 7: 14-21.
48. Malinovszky KM, Cameron D, Douglas S, et al. Breast cancer patients' experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 2004; 13: 363-368.
49. Glaus A, Boehme C, Thurlimann B, et al. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17: 801-806.
50. Sitzia J, Hughes J, Sobrido L. A study of patients' experiences of side-effects associated with chemotherapy: pilot stage report. Int J Nurs Stud 1995; 32: 580-600.
51. Sitzia J, Dikken C, Hughes J. Psychometric evaluation of a questionnaire to document side-effects of chemotherapy. J Adv Nurs 1997; 25: 999-1007.
52. Brown V. The development and evaluation of an instrument to assess the adverse effects of cyctotoxic chemotherapy. 2001; Worthing, Worthing and Southlands Hospitals NHS Trust.
53. Foster JM, Aucott L, van der Werf RH, et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir Med 2006; 106: 1318-1336.
54. Foster JM, van Sonderen E, Lee AJ, et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Resp Res 2006; 7: 131.
55. van der Molen T, Leichtl S, Caeser M. Patient-perceived side effects of Ciclesonide as compared to Fluticasone Propionate in the treatment of moderate asthma using the Inhaled Corticosteroid Questionnaire. Value Health 2006; 9: A336.
56. Lambert TJR, Cock N, Alcock SJ, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol Clin Exp 2003; 18: 405-411.
57. Ward SE, Carlson-Dakes K, Hughes SH, Kwekkeboom KL, Donovan HS. The impact on quality of life of patient-related barriers to pain management. Res Nurs Health 1998; 21: 405-413.
58. Moons P, De Geest S, Abraham I, Cleemput JV, Van Vanhaecke J. Symptom experience associated with maintenance immunosuppression after heart transplantation: patients' appraisal of side effects. Heart Lung 1998; 27: 315-325.
59. Moons P, Vanrenterghem Y, Van Hooff JP, et al. Health-related quality of life and symptom experience in tacrolimus-based regimens after renal transplantation: a multicentre study. Transpl Int 2003; 16: 653-664.
60. Dobbels F, Moons P, Abraham N, De Geest S. Symptom experience in transplant recipients: adaptation and validity of the modified transplant symptom occurrence and symptom distress scale. Am J Transplant 2005; 5: 491.
61. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13: 741-748.
62. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 2004; 31: 615-623.
63. Ostchega Y, Donohue M, Fox N. High-dose cisplatin-related peripheral neuropathy. Cancer Nurs 1988; 11: 23-32.
64. Gillham R, Baker G, Thompson P. et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res 1996; 24: 47-55.
65. Gillham R, Bryant-Comstock L, Kane K. Validation of the side effect and life satisfaction (SEALS) inventory. Seizure 2000; 9: 458-463.
66. Gillham R, Kane K, Bryant-Comstock L, Brodie M. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000; 9: 375-379.
67. Brown SW, Tomlinson LL. Anticonvulsant side-effects: a self report questionnaire for use in community surveys. Br J Clin Pract 1982; 18: 147-149.
68. de Boer WA, Thys JC, Borody TJ, Graham DY, O'Morain C, Tytgat GN. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 641-643.
69. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001; 63: 1-7.